A Phase 1 randomized trial of homologous and heterologous filovirus vaccines with a late booster dose

Filoviruses, including Ebola, Marburg, Sudan, and Taï Forest viruses, are zoonotic pathogens that can cause severe viral hemorrhagic fever and death. Developing vaccines that provide durable, broad immunity against multiple filoviruses is a high global health priority. In this Phase 1 trial, we enro...

Full description

Saved in:
Bibliographic Details
Published in:npj vaccines 2024-12, Vol.9 (1), p.255-13, Article 255
Main Authors: Rostad, Christina A., Yildirim, Inci, Kao, Carol, Yi, Jumi, Kamidani, Satoshi, Peters, Etza, Stephens, Kathleen, Gibson, Theda, Hsiao, Hui-Mien, Singh, Karnail, Spearman, Paul, McCracken, Courtney, Agbakoba, Vivien, Tomashek, Kay M., Goll, Johannes B., Gelber, Casey E., Johnson, Robert A., Lee, Sujin, Maner-Smith, Kristal, Bosinger, Steven, Ortlund, Eric A., Chen, Xuemin, Anderson, Larry J., Wrammert, Jens, Suthar, Mehul, Rouphael, Nadine, Anderson, Evan J.
Format: Article
Language:English
Subjects:
631/250/590
692/699/255/2514
Biomedical and Life Sciences
Biomedicine
Cytotoxicity
Ebola virus
Global health
Immunogenicity
Infectious Diseases
Medical Microbiology
Public Health
Vaccine
Vaccines
Virology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Filoviruses, including Ebola, Marburg, Sudan, and Taï Forest viruses, are zoonotic pathogens that can cause severe viral hemorrhagic fever and death. Developing vaccines that provide durable, broad immunity against multiple filoviruses is a high global health priority. In this Phase 1 trial, we enrolled 60 healthy U.S. adults and evaluated the safety, reactogenicity and immunogenicity of homologous and heterologous MVA-BN®-Filo and Ad26.ZEBOV prime-boost schedules followed in select arms by MVA-BN®-Filo boost at 1 year (NCT02891980). We found that all vaccine regimens had acceptable safety and reactogenicity. The heterologous prime-boost strategy elicited superior Ebola binding and neutralizing antibody, antibody-dependent cellular cytotoxicity (ADCC), and cellular responses compared to homologous prime-boost. The MVA-BN®-Filo boost administered at 1 year resulted in robust humoral and cellular responses that persisted through 6-month follow-up. Overall, our data demonstrated that a heterologous Ad26.ZEBOV/MVA-BN®-Filo prime-boost was safe and immunogenic and established immunologic memory primed to respond after re-exposure. Clinicaltrials.gov, NCT02891980, registered September 1, 2016.
ISSN:2059-0105
2059-0105
DOI:10.1038/s41541-024-01042-4